Intermediate filament: Structure, function, and applications in cytology

Diagnostic Cytopathology

Volumn 42, Issue 7, 2014, Pages 628-635

  Dey, Pranab ^a   Togra, Jyoti ^a   Mitra, Suvradeep ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

carcinoma; cytokeratin; cytology; cytoskeleton; diagnosis; intermediate filaments

Indexed keywords

ALPHA INTERNEXIN; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; DESMIN; KERATIN; KERATIN TYPE I; KERATIN TYPE II; KERATIN TYPE III; KERATIN TYPE IV; KERATIN TYPE V; LAMIN; NESTIN; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN; NES PROTEIN, HUMAN;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; BASAL CELL CARCINOMA; BREAST ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER OF UNKNOWN PRIMARY SITE; CANCER PROGNOSIS; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL SURVIVAL; COLON CARCINOMA; COLORECTAL CARCINOMA; CYTOLOGY; DISEASE FREE SURVIVAL; DOWN REGULATION; ENDOMETRIUM CARCINOMA; EPITHELIOID SARCOMA; EPITHELIUM CELL; FINE NEEDLE ASPIRATION BIOPSY; FINE NEEDLE ASPIRATION CYTOLOGY; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INTERMEDIATE FILAMENT; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MERKEL CELL TUMOR; MESOTHELIOMA; MICROFILAMENT; MICROTUBULE; MOLECULAR WEIGHT; NEUROFILAMENT; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; SQUAMOUS CELL CARCINOMA; SYNOVIAL SARCOMA; TISSUE GROWTH; TISSUE REGENERATION; TRANSITIONAL CELL CARCINOMA; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROTEIN QUATERNARY STRUCTURE;

ANIMALS; DESMIN; HUMANS; INTERMEDIATE FILAMENTS; KERATINS; LAMINS; NEOPLASMS; NESTIN; PROGNOSIS; PROTEIN STRUCTURE, QUATERNARY; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84902553822     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.23132     Document Type: Review

References (57)

1. Fuchs E,. Intermediate filaments: Structure, dynamics, function, and disease. Annu Rev Biochem 1994; 63: 345-382.
2. Cochran DL, Yeoman LC, Egle PM, Shelton KR,. Comparison of the major polypeptides of the erythrocyte nuclear envelope. J Supramol Struct 1979; 10: 405-418.
3. Kaufmann SH, Gibson W, Haper JH,. Characterization of the major polypeptides of the rat liver nuclear envelope. J Biol Chem 1983; 258: 2710-2719.
4. Broers JL, Ramaekers FC, Bonne G, Yaou RB, Hutchison CJ,. Nuclear lamins: Laminopathies and their role in premature ageing. Physiol Rev 2006; 86: 967-1008.
5. Ludérus ME, de Graaf A, Mattia E, et al. Binding of matrix attachment regions to lamin B1. Cell 1992; 70: 949-959.
6. Romig H, Fackelmayer FO, Renz A, Ramsperger U, Richter A,. Characterization of SAF-A, a novel nuclear DNA binding protein from HeLa cells with high affinity for nuclear matrix/scaffold attachment DNA elements. EMBO J 1992; 11: 3431-3440.
7. Steinert PM, Chou YH, Prahlad V, et al. A high molecular weight intermediate filament-associated protein in BHK-21 cells is nestin, a type VI intermediate filament protein. Limited co-assembly in vitro to form heteropolymers with type III vimentin and type IV alpha-internexin. J Biol Chem 1999; 274: 9881-9890.
8. Gounari F, Merdes A, Quinlan R, et al. Bovine filensin possesses primary and secondary structure similarity to intermediate filament proteins. J Cell Biol 1993; 121: 847-853.
9. Chang L, Shav-Tal Y, Trcek T, Singer RH, Goldman RD,. Assembling an intermediate filament network by dynamic cotranslation. J Cell Biol 2006; 172: 747-758.
10. Lu H, Hesse M, Peters B, Magin TM,. Type II keratins precede type I keratins during early embryonic development. Eur J Cell Biol 2005; 84: 709-718.
11. Windoffer R, Leube RE,. Detection of cytokeratin dynamics by time-lapse fluorescence microscopy in living cells. J Cell Sci 1999; 112: 4521-4534.
12. Vikstrom KL, Lim SS, Goldman RD, Borisy GG,. Steady state dynamics of intermediate filament networks. J Cell Biol 1992; 118: 121-129.
13. Windoffer R, Wöll S, Strnad P, Leube RE,. Identification of novel principles of keratin filament network turnover in living cells. Mol Biol Cell 2004; 15: 2436-2448.
14. Lammerding J, Schulze PC, Takahashi T, et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest 2004; 113: 370-378.
15. DePianto D, Coulombe PA,. Intermediate filaments and tissue repair. Exp Cell Res 2004; 301: 68-86.
16. Coulombe PA, Wong P,. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat Cell Biol 2004; 6: 699-706.
17. Caulin C, Ware CF, Magin TM, Oshima RG,. Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol 2000; 149: 17-22.
18. Oshima RG,. Apoptosis and keratin intermediate filaments. Cell Death Differ 2002; 9: 486-492.
19. Moss DK, Lane JD,. Microtubules: Forgotten players in the apoptotic execution phase. Trends Cell Biol 2006; 16: 330-338.
20. Omary MB, Coulomb PA, McLean WH,. Intermediate filament proteins and their associated diseases. New Engl J Med 2004; 351: 2087-2100.
21. Styers ML, Kowalczyk AP, Faundez V,. Intermediate filaments and vesicular membrane traffic: The odd couple's first dance? Traffic 2005; 6: 359-365.
22. Colucci-Guyon E, Portier MM, Dunia I, Paulin D, Pournin S, Babinet C,. Mice lacking vimentin develop and reproduce without an obvious phenotype. Cell 1994; 79: 679-694.
23. Pan X, Hobbs RP, Coulombe PA,. The expanding significance of keratin intermediate filaments in normal and diseased epithelia. Curr Opin Cell Biol 2012; 25: 1-10.
24. Sun TT, Eichner R, Nelson WG,. Keratin classes: Molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983; 81: 109s-115s.
25. Chu PG, Weiss LM,. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-439.
26. Moll R, Divo M, Langbein L,. The human keratin: Biology and pathology. Hisochem Cell Biol 2008; 129: 705-733.
27. Blumenfeld W, Turi GK, Harrison G, Latuszynski D, Zhang C,. Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens. Diagn Cytopathol 1999; 20: 63-66.
28. Sack MJ, Roberts SA,. Cytokeratins 20 and 7 in the differential diagnosis of metastatic carcinoma in cytologic specimens. Diagn Cytopathol 1997; 16: 132-136.
29. Ascoli V, Taccogna S, Scalzo CC, Nardi F,. Utility of cytokeratin 20 in identifying the origin of metastatic carcinomas in effusions. Diagn Cytopathol 1995; 12: 303-308.
30. Jang KY, Kang MJ, Lee DG, Chung MJ,. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001; 23: 400-404.
31. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: A retrospective study of 103 cases with surgical correlation. Cancer 2011; 117: 3416-3423.
32. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL,. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011; 24: 1348-1359.
33. Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998; 42: 1382-1388.
34. Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT,. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001; 93: 330-336.
35. Bhatia A, Dey P, Kumar Y, et al. Expression of cytokeratin 20 in urine cytology smears: A potential marker for the detection of urothelial carcinoma. Cytopathology 2007; 18: 84-86.
36. Lin S, Hirschowitz SL, Williams C, Shintako P, Said J, Rao JY,. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: Preliminary retrospective study on archived urine slides. Cancer Detect Prev 2001; 25: 202-209.
37. Knösel T, Emde V, Schluns K, Schlag PM, Dietel M, Petersen I,. Cytokeratin proWles identify diagnostic signatures in colorectal cancer using multiplex analysis of tissue microarrays. Cell Oncol 2006; 28: 167-175.
38. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR,. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol 2004; 28: 712-718.
39. Ausch C, Buxhofer-Ausch V, Olszewski U, Hinterberger W, Ogris E, Schiessel R,. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol 2009; 35: 1164-1168.
40. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A,. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 2001; 61: 5168-5178.
41. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J,. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996.
42. Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19: 3549-3552.
43. Devine PL, Yarker J, Fong K,. Serum markers CASA, CEA, CYFRA 21-1, MSA, NSE, TPA and TPS in lung cancer. Int J Oncol 1994; 4: 1129-1135.
44. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, Karadag M,. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 2007; 56: 399-404.
45. Yang XR, Xu Y, Shi GM, Fan J, Zhou J, Ji Y,. Cytokeratin 10 and cytokeratin 19: Predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res 2008; 14: 3850-3859.
46. Bluemke K, Bilkenroth U, Meye A, Fuessel S, Lautenschlaeger C, Goebel S,. Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. Cancer Epidemiol Biomark Prev 2009; 18: 2190-2194.
47. Larsson A, Wilhelmsson U, Pekna M, Pekny M,. Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP(-/-)Vim(-/-) mice. Neurochem Res 2004; 29: 2069-2073.
48. Zhao Y, Yan Q, Long X, Chen X, Wang Y,. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem Funct 2008; 26: 571-577.
49. Domagala W, Lasota J, Bartkowiak J, Weber K, Osborn M,. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990; 136: 219-227.
50. Wei J, Xu G, Wu M, et al. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res 2008; 28: 327-334.
51. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H,. Clinical significance of basal-like subtype in triple-negative breast cancer. Breast Cancer 2009; 16: 260-267.
52. Upton MP, Hirohashi S, Tome Y, Miyazawa N, Suemasu K, Shimosato Y,. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986; 10: 560-567.
53. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT,. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Brit J Cancer 2008; 99: 1476-1483.
54. Thiery JP,. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
55. Truong LD, Rangdaeng S, Cagle PT, Ro JY, Hawkins H, Font RL,. The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 1990; 93: 305-314.
56. Gautam U, Srinivasan R, Rajwanshi A, Bansal D, Marwaha RK,. Comparative evaluation of flow-cytometric immunophenotyping and immunocytochemistry in the categorization of malignant small round cell tumors in fine-needle aspiration cytologic specimens. Cancer 2008; 114: 494-503.
57. Domagała W, Chosia M, Bedner E, Kubicka C, Weber K, Osborn M,. Immunocytochemistry in fine needle aspirates of small cell-, round-, blue-cell malignant tumors of childhood (neuroblastoma, nephroblastoma, lymphoma, Ewing's sarcoma, rhabdomyosarcoma). Patol Pol 1991; 42: 79-82.